Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP)

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 4, 2014, Pages 673-679

  Kitagawa, Yasuhide ^a   Ueno, Satoru ^a   Izumi, Kouji ^a   Mizokami, Atsushi ^a   Hinotsu, Shiro ^b   Akaza, Hideyuki ^c   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Nadir PSA level; Outcome predictor; Primary androgen deprivation; Prostate cancer; Time to PSA nadir

Indexed keywords

BICALUTAMIDE; CHLORMADINONE ACETATE; DIETHYLSTILBESTROL; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; COHORT ANALYSIS; DATA BASE; DISTANT METASTASIS; FOLLOW UP; GLEASON SCORE; HUMAN; JAPAN CANCER OF THE PROSTATE ASSESSMENT SCORE; JAPANESE (PEOPLE); LOW RISK POPULATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; REGISTER; SCORING SYSTEM;

ADULT; AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84899492876     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1612-8     Document Type: Article

References (21)

1. Akaza H, Usami M, Hinotsu S et al (2004) Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance. Jpn J Clin Oncol 34:329-336 (Pubitemid 43115314)
2. Akaza H, Homma Y, Usami M et al (2006) Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU Int 98:573-579 (Pubitemid 44185879)
3. Arai Y, Yoshiki T, Yoshida O (1990) Prognostic significance of prostate specific antigen in endocrine treatment for prostate cancer. J Urol 144:1415-1419
4. Choueiri TK, Xie W, D'Amico AV et al (2009) Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 115:981-987
5. Cooper EH, Armitage TG, Robinson MR et al (1990) Prostatic specific antigen and the prediction of prognosis in metastatic prostatic cancer. Cancer 66:1025-1028 (Pubitemid 20293000)
6. Cooperberg MR, Hinotsu S, Namiki M et al (2009) Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 27:4306-4313
7. Harlan LC, Potosky A, Gilliland FD et al (2001) Factors associated with initial therapy for clinically localized prostate cancer: prostate cancer outcomes study. J Natl Cancer Inst 93:1864-1871 (Pubitemid 34048653)
8. Heidenreich A, Aus G, Bolla M et al (2008) EAU guidelines on prostate cancer. Eur Urol 53:68-80 (Pubitemid 350166735)
9. Hinotsu S, Akaza H, Usami M et al (2007) Current status of endocrine therapy for prostate cancer in Japan analysis of primary androgen deprivation therapy on the basis of data collected by J-CaP. Jpn J Clin Oncol 37:775-781 (Pubitemid 350120301)
10. Hori S, Jabbar T, Kachroo N, Vasconcelos JC, Robson CN, Gnanapragasam VJ (2011) Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 137:235-241
11. Huang SP, Bao BY, Wu MT et al (2011) Impact of prostate-specific antigen (PSA) nadir and time to PSA nadir on disease progression in prostate cancer treated with androgen-deprivation therapy. Prostate 71:1189-1197
12. Huggins C, Hodges C (1972) Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin 22:232-240
13. Hussain M, Tangen CM, Higano C et al (2006) Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from southwest oncology group trial 9346 (INT-0162). J Clin Oncol 24:3984-3990 (Pubitemid 46630748)
14. International Union Against Cancer (1997) Urologic tumors: prostate. In: Sobin LH, Wittekind CH (eds) TNM classification of malignant tumours, 5th edn. Wiley, New York, pp 170-173
15. Keto CJ, Aronson WJ, Terris MK et al (2012) Detectable prostate-specific antigen nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database. Eur Urol. doi:10.1016/j.eururo.2012.11.052
16. Kitagawa Y, Hinotsu S, Shigehara K et al (2013) Japan Cancer of the Prostate Risk Assessment for combined androgen blockade including bicalutamide: clinical application and validation. Int J Urol 20:708-714
17. Kwak C, Jeon SJ, Park MS, Lee E, Lee SE (2002) Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J Urol 168:995-1000
18. Labrie F, Candas B, Gomez JL, Cusan L (2002) Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer? Urology 60:115-119 (Pubitemid 34722958)
19. Morote J, Trilla E, Esquena S, Abascal JM, Reventos J (2004) Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer. Int J Cancer 108:877-881 (Pubitemid 38112617)
20. Petros JA, Andriole GL (1993) Serum PSA after antiandrogen therapy. Urol Clin North Am 20:749-756 (Pubitemid 24141168)
21. Sasaki T, Onishi T, Hoshina A (2012) Cutoff value of time to pros-tate- specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer. Endocr Relat Cancer 19:725-730